Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $14.0M | $9.04M | $6.94M |
| Revenue growth | — | — | — | — | — | -35.5% | -23.2% |
| Operating income | -$10.3M | -$12.3M | -$25.2M | -$36.9M | -$110M | -$306M | -$224M |
| Operating margin | — | — | — | — | -781.4% | -3382.4% | -3228.8% |
| Net income | -$10.4M | -$17.8M | -$24.7M | -$36.9M | -$107M | -$293M | -$212M |
| Net margin | — | — | — | — | -761.9% | -3240.4% | -3060.0% |
| EPS (diluted) | -$9.55 | -$5.26 | -$2.14 | -$3.09 | -$5.38 | -$5.00 | -$2.43 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.60M | -$12.1M | -$18.2M | -$28.7M | -$7.57M | -$111M | -$191M |
| Capital expenditures | $233K | $586K | $79.0K | $248K | $831K | $7.17M | $9.69M |
| Free cash flow | -$9.83M | -$12.7M | -$18.3M | -$28.9M | -$8.40M | -$118M | -$201M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.54M | $39.8M | $49.2M | $20.3M | $98.7M | $143M | $653M |
| Total assets | $5.06M | $44.5M | $57.9M | $24.0M | $149M | $240M | $683M |
| Total liabilities | $1.80M | $3.18M | $9.74M | $7.39M | $28.7M | $59.1M | $48.8M |
| Long-term debt | — | $134K | — | — | — | — | — |
| Shareholders' equity | -$35.6M | $41.3M | $48.2M | $16.7M | $120M | $181M | $634M |
| Retained earnings | -$36.6M | -$54.4M | -$79.1M | -$116M | -$223M | -$516M | -$728M |
| Shares (wtd avg diluted) | 1.10M | 3.39M | 11.5M | 12.1M | 19.8M | 58.6M | 87.4M |
Every figure is extracted from Immunome Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.